Hepatic fibrosis and the renin-angiotensin system

American Journal of Therapeutics

Volumn 18, Issue 6, 2011, Pages

  Abbas, Ghulam ^a   Silveira, Marina G ^a   Lindor, Keith D ^a  

^a MAYO CLINIC   (United States)

Author keywords

angiotensin converting enzyme 2; hepatic fibrosis; renin angiotensin system

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; INTERLEUKIN 6; IRBESARTAN; LISINOPRIL; LOSARTAN; NEUROTENSIN[8-13]; PERINDOPRIL; TRANSFORMING GROWTH FACTOR BETA1; VALSARTAN;

ALCOHOL LIVER CIRRHOSIS; ARTICLE; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; DISEASE COURSE; GENETIC POLYMORPHISM; HEPATITIS C; HUMAN; LIVER FIBROSIS; NONHUMAN; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STELLATE CELL;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; HEPATIC STELLATE CELLS; HUMANS; LIVER CIRRHOSIS; PEPTIDYL-DIPEPTIDASE A; RENIN-ANGIOTENSIN SYSTEM; TRANSFORMING GROWTH FACTOR BETA1;

EID: 81755163663     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181df8df5     Document Type: Article

References (63)

1. Kochanek KD, Smith BL. Deaths: preliminary data for 2002. Natl Vital Stat Rep. 2004;52:1-47.
2. Pereira RM, Dos Santos RA, Teixeira MM, et al. The reninangiotensin system in a rat model of hepatic fibrosis: evidence for a protective role of Angiotensin-(1-7). J Hepatol. 2007;46:674-681. (Pubitemid 46400144)
3. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol. 2002;89:3A-9A. Discussion 10A.
4. Yu L, Noble NA, Border WA. Therapeutic strategies to halt renal fibrosis. Curr Opin Pharmacol. 2002;2:177-181. (Pubitemid 34296448)
5. Bataller R, Sancho-Bru P, Gines P, et al. Liver fibrogenesis: a new role for the renin-angiotensin system. Antioxid Redox Signal. 2005;7:1346-1355. (Pubitemid 41232532)
6. Bataller R, Gines P, Nicolas JM, et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology. 2000;118:1149-1156. (Pubitemid 30346992)
7. Bataller R, Gabele E, Parsons CJ, et al. Systemic infusion of angiotensin II exacerbates liver fibrosis in bile ductligated rats. Hepatology. 2005;41:1046-1055. (Pubitemid 40593912)
8. Croquet V, Moal F, Veal N, et al. Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension. J Hepatol. 2002;37:773-780. (Pubitemid 35404216)
9. Jonsson JR, Clouston AD, Ando Y, et al. Angiotensinconverting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology. 2001;121:148-155. (Pubitemid 32591525)
10. Kurikawa N, Suga M, Kuroda S, et al. An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells. Br J Pharmacol. 2003;139:1085-1094. (Pubitemid 36920670)
11. Terui Y, Saito T, Watanabe H, et al. Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C. Hepatology. 2002;36:1022.
12. Rimola A, Londono MC, Guevara G, et al. Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation. Transplantation. 2004;78:686-691. (Pubitemid 39244729)
13. Schneider AW, Kalk JF, Klein CP. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology. 1999;29:334-339. (Pubitemid 29088434)
14. Yokohama S, Yoneda M, Haneda M, et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology. 2004;40:1222-1225. (Pubitemid 39425579)
15. Debernardi-Venon W, Martini S, Biasi F, et al. AT1 receptor antagonist Candesartan in selected cirrhotic patients: effect on portal pressure and liver fibrosis markers. J Hepatol. 2007;46:1026-1033. (Pubitemid 46669730)
16. Corey KE, Shah N, Misdraji J, et al. The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. Liver Int. 2009;29:748-753.
17. Sookoian S, Fernandez MA, Castano G. Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: a pilot study. World J Gastroenterol. 2005;11:7560-7563. (Pubitemid 43168416)
18. Wagatsuma Y, Naritaka Y, Shimakawa T, et al. Clinical usefulness of the angiotensin II receptor antagonist losartan in patients with portal hypertensive gastropathy. Hepatogastroenterology. 2006;53:171-174.
19. Winkelmayer WC, Zhang Z, Shahinfar S, et al. Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes. Diabetes Care. 2006;29: 2210-2217. (Pubitemid 44899854)
20. Bernardi M, Trevisani F, Gasbarrini A, et al. Hepatorenal disorders: role of the renin-angiotensin-aldosterone system. Semin Liver Dis. 1994;14:23-34. (Pubitemid 24116690)
21. Paizis G, Gilbert RE, Cooper ME, et al. Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. J Hepatol. 2001;35:376-385. (Pubitemid 32844192)
22. Blendis L, Wong F. The hyperdynamic circulation in cirrhosis: an overview. Pharmacol Ther. 2001;89:221-231. (Pubitemid 32539409)
23. Kamada Y, Tamura S, Kiso S, et al. Angiotensin II stimulates the nuclear translocation of Smad2 and induces PAI-1 mRNA in rat hepatic stellate cells. Hepatol Res. 2003;25:296-305. (Pubitemid 36546356)
24. Kitamura K, Tada S, Nakamoto N, et al. Rho/Rho kinase is a key enzyme system involved in the angiotensin II signaling pathway of liver fibrosis and steatosis. J Gastroenterol Hepatol. 2007;22:2022-2033. (Pubitemid 47525076)
25. De Minicis S, Brenner DA. NOX in liver fibrosis. Arch Biochem Biophys. 2007;462:266-272. (Pubitemid 46856330)
26. Bataller R, Schwabe RF, Choi YH, et al. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest. 2003;112: 1383-1394. (Pubitemid 38057692)
27. Li X, Meng Y, Zhang ZS, et al. [Effect of ACE-I and AT-1 receptor blocker on the progression of CCl(4)-inducing rat hepatic fibrogenesis. Zhonghua Yi Xue Za Zhi. 2003;83: 1241-1245 [in Chinese].
28. Li X, Meng Y, Yang XS, et al. Perindopril attenuates the progression of CCl4-inducing rat hepatic fibrosis. Zhonghua Gan Zang Bing Za Zhi. 2004;12:32-34 [in Chinese].
29. Yoshiji H, Yoshii J, Ikenaka Y, et al. Inhibition of reninangiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats. J Hepatol. 2002;37:22-30. (Pubitemid 34713051)
30. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005; 115:209-218. (Pubitemid 40385459)
31. Bataller R, North KE, Brenner DA. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology. 2003;37:493-503. (Pubitemid 36258768)
32. Dorer FE, Kahn JR, Lentz KE, et al. Purification and properties of angiotensin-converting enzyme from hog lung. Circ Res. 1972;31:356-366.
33. Skeggs LT, Lentz KE, Gould AB, et al. Biochemistry and kinetics of the renin-angiotensin system. Fed Proc. 1967;26: 42-47.
34. Johnston CI, Burrell LM, Perich R, et al. The tissue reninangiotensin system and its functional role. Clin Exp Pharmacol Physiol Suppl. 1992;19:1-5.
35. Bataller R, Sancho-Bru P, Gines P, et al. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology. 2003;125: 117-125. (Pubitemid 36799113)
36. Paizis G, Cooper ME, Schembri JM, et al. Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. Gastroenterology. 2002;123: 1667-1676. (Pubitemid 35231666)
37. Sakata T, Takenaga N, Endoh T, et al. Diagnostic significance of serum angiotensin-converting enzyme activity in biochemical tests with special reference of chronic liver diseases. Jpn J Med. 1991;30:402-407.
38. Morris BJ, Iwamoto HS, Reid IA. Localization of angiotensinogen in rat liver by immunocytochemistry. Endocrinology. 1979;105:796-800. (Pubitemid 9257473)
39. Sawa H. Angiotensinogen: gene expression and protein localization in human tissues. Hokkaido Igaku Zasshi. 1990; 65:189-199 [in Japanese].
40. Yoshiji H, Kuriyama S, Yoshii J, et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology. 2001;34:745-750. (Pubitemid 32927999)
41. Kanno K, Tazuma S, Chayama K. AT1A-deficient mice show less severe progression of liver fibrosis induced by CCl(4). Biochem Biophys Res Commun. 2003;308:177-183. (Pubitemid 36904138)
42. Yang L, Bataller R, Dulyx J, et al. Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice. J Hepatol. 2005;43:317-323. (Pubitemid 40956886)
43. Bataller R, Gabele E, Schoonhoven R, et al. Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proinflammatory events in liver. Am J Physiol Gastrointest Liver Physiol. 2003;285:G642-G651. (Pubitemid 37021824)
44. Rice GI, Thomas DA, Grant PJ, et al. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J. 2004;383:45-51. (Pubitemid 39389449)
45. Vickers C, Hales P, Kaushik V, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem. 2002;277: 14838-14843. (Pubitemid 34952556)
46. Burrell LM, Johnston CI, Tikellis C, et al. ACE2, a new regulator of the renin-angiotensin system. Trends Endocrinol Metab. 2004;15:166-169. (Pubitemid 38510496)
47. Huentelman MJ, Grobe JL, Vazquez J, et al. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol. 2005;90:783-790. (Pubitemid 41406067)
48. Diez-Freire C, Vazquez J, Correa de Adjounian MF, et al. ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. Physiol Genomics. 2006;27:12-19. (Pubitemid 44511821)
49. Grobe JL, Mecca AP, Lingis M, et al. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am J Physiol Heart Circ Physiol. 2007;292: H736-H742.
50. Arthur MJ. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology. 2002; 122:1525-1528. (Pubitemid 34465193)
51. Issa R, Zhou X, Constandinou CM, et al. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix crosslinking. Gastroenterology. 2004;126:1795-1808. (Pubitemid 38736345)
52. Bataller R, Brenner DA. Hepatic stellate cells as a target for the treatment of liver fibrosis. Semin Liver Dis. 2001;21: 437-451. (Pubitemid 32923771)
53. Osterreicher CH, Taura K, DeMinicis S, et al. Angiotensinconverting- enzyme 2 inhibits liver fibrosis in mice. Hepatology. 2009;50:929-938.
54. Park DH, Baik SK, Choi YH, et al. Inhibitory effect of angiotensin blockade on hepatic fibrosis in common bile duct-ligated rats. Korean J Hepatol. 2007;13:61-69 [in Korean].
55. Toblli JE, Munoz MC, Cao G, et al. ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats. Obesity (Silver Spring). 2008;16:770-776. (Pubitemid 351465631)
56. Ohishi T, Saito H, Tsusaka K, et al. Anti-fibrogenic effect of an angiotensin converting enzyme inhibitor on chronic carbon tetrachloride-induced hepatic fibrosis in rats. Hepatol Res. 2001;21:147-158. (Pubitemid 32899085)
57. Xu W, Song S, Huang Y, et al. Effects of perindopril and valsartan on expression of transforming growth factorbeta- Smads in experimental hepatic fibrosis in rats. J Gastroenterol Hepatol. 2006;21:1250-1256. (Pubitemid 44034336)
58. Tuncer I, Ozbek H, Ugras S, et al. Anti-fibrogenic effects of captopril and candesartan cilexetil on the hepatic fibrosis development in rat. The effect of AT1-R blocker on the hepatic fibrosis. Exp Toxicol Pathol. 2003;55:159-166. (Pubitemid 37309765)
59. Turkay C, Yonem O, Arici S, et al. Effect of angiotensinconverting enzyme inhibition on experimental hepatic fibrogenesis. Dig Dis Sci. 2008;53:789-793. (Pubitemid 351317094)
60. Vilas-Boas WW, Ribeiro-Oliveira A Jr, Pereira RM, et al. Relationship between angiotensin-(1-7) and angiotensin II correlates with hemodynamic changes in human liver cirrhosis. World J Gastroenterol. 2009;15:2512-2519.
61. Dixon JB, Bhathal PS, Jonsson JR, et al. Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese. J Hepatol. 2003;39:967-971. (Pubitemid 37523767)
62. Powell EE, Edwards-Smith CJ, Hay JL, et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology. 2000;31:828-833. (Pubitemid 30169926)
63. Schiffrin EL. Vascular and cardiac benefits of angiotensin receptor blockers. Am J Med. 2002;113:409-418. (Pubitemid 35230007)